Log-rank univariate survival analysis showed the OS and DFS rates of TNBCs with axillary lymph node metastasis were 38.1% and 23.8%, respectively, and the OS and DFS rates of triple negative breast cancer with axillary lymph node non-metastasis were 93.8% and 75.0%, respectively. There were ...
Triple-negative breast cancer is more aggressive than other forms. It’s more likely to have spread beyond your breast at the time it’s found, and there’s a higher chance it will come back within the first 3 years after treatment. It’s also more likely to be fatal within the first ...
Triple-negative breast cancer (TNBC) is the most aggressive subtype with the worst prognosis and the highest metastatic and recurrence potential, which represents 15–20% of all breast cancers in Chinese females, and the 5-year overall survival rate is about 80% in Chinese women. Recently, emer...
To find metastatic recurrence biomarkers of triple-negative breast cancer (TNBC) treated by neoadjuvant chemotherapy and anti-EGFR antibodies (NAT), we evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, gene arrays, Nan
This study focused on triple-negative breast cancer (TNBC) that is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2). The primary goal of this study was to describe the relation between triple-...
SurvivalTo determine the incidence, characteristics, and survival outcomes of triple-negative breast cancer patients in a medical oncology practice in Lebanon.The pathology reports of all breast cancer cases diagnosed or treated in 1997-2008 were reviewed.One hundred seventy breast cancer cases (9.3%)...
Multiple studies have shown that African American women with breast cancer have lower survival rates than white women with the disease. But the association between race or ethnicity and treatment outcomes in triple-negative breast cancer—an aggressive t
Objective To determine factors associated with the survival of patients with metastatic recurrent triple-negative breast cancer(mrTNBC).Methods Initial metastatic recurrent(during or after therapy)patients with triple-negative breast cancer(TNBC)confirmed by post-operate pathology in the West China Hospital...
What Are the Mortality Rates for Triple-Negative Breast Cancer? The overall five-year survival rate for TNBC is 77.1%.1Broken down by stage for TNBC, it is as follows:1 Localized: 91.3% Regional: 65.8% Distant: 12.0% The survival rates may be related to the fact that TNBC is often dia...
Capivasertib's safety profile in the CAPItello-290 trial was comparable with prior reports of the agent in advanced triple-negative breast cancer. Questions Remain Around Neoadjuvant Chemoimmunotherapy in TNBC By Kristie L. Kahl April 23rd 2024 Survival Outcomes Improve With TIL Presence in TNBC By...